Abstract: This invention provides intermediates useful in a method of preparing amine stereoisomers. It also provides a method of preparing sulfoxide and sulfinylamine stereoisomers using certain of the intermediates.

Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.

Abstract: This invention encompasses novel methods of preparing sulfinamides and sulfoxides, particularly stereomerically pure sulfinamides and sulfoxides. The invention further encompasses novel compounds from which sulfinamides and sulfoxides can be prepared.

Abstract: Compounds of formula I in which R1, R2, R3, each X, L, Y, Cy, Lp, D and n have the meanings as set out in the specification, and corresponding compounds in which the unsubstituted or substituted amidine group is replaced with an unsubstituted or substituted aminomethyl group, are useful as serine protease inhibitors.

Abstract: Compounds of formula (I) where R5, R6a, each X, L, Cy and Lp are as defined in the specification, are tryptase inhibitors useful as antiinflammatory agents.

Abstract: This invention provides a method of preparing amine stereoisomers, which comprises stereoselectively reducing a sulfinylimine that bears on the sulfinyl group a residue of an alcohol, thiol or amine, or reacting a sulfinylimine stereoisomer that bears on the sulfinyl group a residue of an alcohol, thiol or amine with a source of a nucleophile, to afford a sulfinylamine stereoisomer, followed by contacting the sulfinylamine stereoisomer with a reagent suitable for the cleavage of a sulfur-nitrogen bond, to afford an amine stereoisomer. It also provides novel intermediates useful in the method, and the use of certain of the intermediates in the preparation of sulfoxide and sulfinylamine stereoisomers.

Abstract: Compounds of formula (I) where R2, each X, L, Y, Cy, Lp, D and n are as defined in the specification, are serine protease inhibitors useful as antithrombotic agents.

Abstract: Compounds of formula (I) where R5, R6a, each X, L, Cy and Lp are as defined in the specification, are tryptase inhibitors useful as antiinflammatory agents.

Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.

Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.

Abstract: Compounds of formula (I) where R5, R6a, each X, L, Cy and Lp are as defined in the specification, are tryptase inhibitors useful as antiinflammatory agents.

Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.

Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.

Abstract: Compounds of formula (I) where R2, each X, L, Y, Cy, Lp, D and n are as defined in the specification, are serine protease inhibitors useful as antithrombotic agents.

Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, factor Xa and are useful in the treatment of cardiovascular disorders.

Abstract: The novel compound 3-amidinobenzoyl-D-phenylglycine-3-phenylanilide is useful as a serine protease inhibitor.

Abstract: A method of identifying a ligand for a second binding site (5) on a biological substrate (1) is disclosed. The method comprises determining the effect of a candidate compound (9) on the binding of a probe compound (2) which binds to a first binding site (3) on the biological substrate in the presence of a first multibinding compound (4) which binds to the first (3) and second (5) binding sites on the biological substrate (1).

Abstract: A ladder is provided which has considerably reduced tendency to slip. Typically, the ladder 1 has rungs 5 and side members 2 with end caps 3 resting on the ground 4. Securing member 6, made typically from aluminium alloy, has friction member 7 provided with spikes 16. Pivot member 8 on the securing member 6 is fixed at one end on the securing member to opposite sides of the securing member, and at the other end is mounted through bolt 9 to the side member of the ladder. Flat spring 17 is fitted around the bolts 9, the spring being biassed to bring the securing member 6 against the side member 2. The pivot member is arcuate in shape to allow the securing member, when not in use to be positioned essentially flat against the ladder and not proud of the lower end of the side member. In use, the ladder is placed on the ground and against a wall. The securing member is pivoted against the bias of spring 17 so as to place it on the ground.

Abstract: An apparatus is provided for a portable ladder which has essentially parallel side members, the apparatus comprising having a pair of arcuate arms for attachment to the upper end of each side member of the ladder, at least one resilient roller mounted on a corresponding axle or axles located between and/or outwardly from the arms, a mechanism to locate each arm on each side member and a mechanism to secure the arms to the side member, the width of the roller being at least 50% of the distance between the arms. Also provided is a ladder fitted with the above apparatus. A ladder fitted with the apparatus enables easier working for a workman working at the top of the ladder and reduces possible damage to the surface on which the top of the ladder rests.

Abstract: A method of alleviating a fibrotic disease selected from lung fibrosis and liver cirrhosis in a warm blooded animal, which comprises administering an effective amount of at least one compound having the formula (I) in which X stands for the oxygen or sulphur atom or for the imino (—NH—) or sulphonyl (—SO2—) radical, Y stands for a direct linkage, or for the oxygen or sulphur atom or for the sulphonyl (—SO2—) radical or for the radical of the formula —CR1R2—, wherein R1 and R2 which may be the same or different are hydrogen, alkyl or aryl radicals or R1 and R2 may be joined together to form a cycloalkyl ring, n is an integer having the value 0 or 1, provided that when n is 0, Y stands for the oxygen or sulphur atom or for the sulphonyl (—SO2—) radical, or an ester, amide or salt thereof.